<DOC>
	<DOCNO>NCT01164046</DOCNO>
	<brief_summary>Background Patients cancer first deep venous thrombosis leg pulmonary embolism ( venous thromboembolism , VTE ) generally treat low molecular weight heparin ( LMWH ) injections 6 month , since treatment associate reduced incidence recurrent VTE compare vitamin K antagonist ( VKA ) . It recommend patient active malignancy ( metastatic cancer and/or ongoing cancer treatment ) continue anticoagulant treatment . However , unknown whether LMWH still superior compare VKA long-term anticoagulant treatment . Aim The aim study evaluate whether low-molecular-weight heparin effectively reduce recurrent VTE compare vitamin K antagonists patient cancer already complete 6 12 month anticoagulant treatment deep venous thrombosis leg pulmonary embolism . Hypothesis The investigator hypothesize LMWH effective compare VKA long-term treatment VTE cancer patient already treat 6-12 month anticoagulant . Design This multicenter , multinational , randomize , open label trial . Patients Patients malignancy ( type , solid hematological ) receive 6-12 month anticoagulation VTE indication continue anticoagulation , randomly assign six additional month LMWH VKA . LMWH administer weight-adjusted scheme , 65-75 % therapeutic dos . All type LMWH VKA allow , long weight adjust dose possible LMWH . The target INR 2.0-3.0 . The primary efficacy outcome symptomatic recurrent VTE , i.e . deep vein thrombosis pulmonary embolism . The primary safety outcome major bleeding . Sample size A total 65 87 recurrent VTE event need show 50 % reduction LMWH compare VKA ( type I error 0.05 , two-sided , power respectively 80 90 % ) . To observe 75 event , 10 % event rate per half year VKA arm 5 % LMWH arm total 1000 patient need include . Organisation Outcomes adjudicate central adjudication committee . A steer committee form , preferably consist one member every participating center . An electronic case report form use data collection . Also , electronic trial master file use .</brief_summary>
	<brief_title>Long-term Treatment Cancer Patients With Deep Venous Thrombosis Pulmonary Embolism</brief_title>
	<detailed_description>Venous thromboembolism ( VTE ) , include deep venous thrombosis ( DVT ) pulmonary embolism ( PE ) , represent major cause morbidity mortality cancer patient . 1 The risk VTE increase several-fold patient cancer incidence range 4 % 20 % . 2 Treatment VTE aim prevent recurrent event , include potentially fatal PE , turn could reduce morbidity , use health care resource , , mortality cancer patient . Standard treatment VTE consist initial course heparin follow vitamin K antagonist ( VKAs ) dose adjust maintain international normalize ratio ( INR ) 2.0 3.0 . Several unique aspect relate cancer management make VKA therapy complex non cancer patient . Chemotherapy induce thrombocytopenia invasive procedure , instance , may require temporary interruption anticoagulant therapy prompt reversal anticoagulant effect . On side , poor nutrition , concomitant medication , impair liver function cause unpredictable change dose response VKAs . In addition , VKAs seem less effective safe cancer patient experience 3-fold high risk VTE recurrence 3-fold high risk bleed anticoagulation compare patient without cancer . 3-5 Most bleeding thrombotic complication occur anticoagulant parameter within therapeutic range . Therefore , aggressive anticoagulant therapy would potential reduce risk recurrent VTE , price increase bleeding . Recently , randomize clinical trial prospective cohort study cancer patient acute VTE show low-molecular-weight heparin ( LMWH ) may effective prevent VTE recurrence comparable bleed risk compare VKA 's . 6-9 In addition , LMWH offer advantage easy administer , flexible , influenced nutrition problem liver impairment . In CLOT ( Randomized Comparison Low-Molecular-Weight Heparin Versus Oral Anticoagulant Therapy Prevention Recurrent Venous Thromboembolism Patients Cancer ) study , cancer patient acute , symptomatic proximal DVT , PE , , randomly assign receive dalteparin ( 200 IU/kg body weight subcutaneously daily 5 7 day ) follow coumarin derivative 6 month , dalteparin alone 6 month ( 200 IU/kg body weight daily 1 month follow 150 IU/kg body weight daily 5 month ) . During 6-month study period , 27 336 patient ( 9 % ) dalteparin group symptomatic , objectively document recurrent VTE compare 53 336 patient ( 17 % ) VKAs group , hazard ratio 0.48 ( 95 % CI : 0.30 , 0.77 , p=0.002 ) . There statistically significant difference major bleeding ( 6 % versus 4 % , p=0.27 ) bleeding ( 14 % 19 % , respectively , p=0.09 ) two study group . 6 In randomize , open-label multicenter trial , subcutaneous enoxaparin sodium ( 1.5 mg/kg daily ) compare warfarin give 3 month 146 cancer patient VTE . 7 Fifteen ( 21.1 % ) 71 assessable patient assign receive warfarin one major bleed recurrent VTE within 3 month compare seven patient ( 10.5 % ) 67 assessable patient assign receive enoxaparin ( p=0.09 ) . There six death result hemorrhage warfarin group compare none enoxaparin group . In RCT 122 cancer patient acute symptomatic VTE , significant difference major minor bleeding rate observe patient assign subcutaneous enoxaparin give 180 day receive enoxaparin follow warfarin . 8 In LITE ( Longitudinal Investigation Thromboembolism Etiology ) study , cancer patient acute symptomatic proximal DVT randomize intravenous UFH follow VKAs 3 month tinzaparin ( 175 U/kg daily ) alone 3 month . During 1-year observational period , recurrent VTE occur 16 100 ( 16 % ) patient assign UFH-VKAs compare 7 100 cancer patient ( 7 % ) treat tinzaparin . 9 The American Society Clinical Oncology American College Chest Physicians guideline advice LMWH acute long-term treatment cancer patient acute VTE . 10-11 The US Food Drug Administration recently approve dalteparin sodium long-term treatment symptomatic VTE cancer patient . 12 Long-term anticoagulant therapy VKAs suggest LMWH available . After 6 month LMWH , indefinite anticoagulant therapy suggest patient active cancer , metastases receive chemotherapy . These patient consider great risk recurrent VTE . For patient , mean lifelong anticoagulation . The relative benefit risk continue LMWH beyond 6 month versus switch oral VKAs , remain clinical judgment individual patient . Some expert field recommend VKAs patient less advanced disease . 13 The risk long-term LMWH therapy include bleeding , heparin-induced thrombocytopenia osteoporosis . While heparin-induced thrombocytopenia clinically relevant osteoporosis seem relatively uncommon , incidence major overall bleeding appear comparable LMWH VKAs least first 3-6 month therapy . 6-8 The cost long-term LMWH administration exceed far VKAs 14 well patient 's preference take account decide optimal long-term VTE prophylaxis . The optimal anticoagulant prophylaxis cancer patient VTE complete 6 month LMWH remain dilemma . While current guideline American Society Clinical Oncology American College Chest Physicians advice lifelong LMWH , recommendation remain base solely expert consensus absence clinical trial data . A recent worldwide survey show VKAs remain commonly use long-term cancer patient . 15 The aim study evaluate whether LMWHs superior VKAs long-term treatment symptomatic VTE cancer patient complete 6 12 month anticoagulant treatment . As state , medicine use decade side-effects widely know . In study , dictate anticoagulant use long-term treatment , whether anticoagulant treatment indicate .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<criteria>1 . Patients cancer confirm pulmonary embolism ( PE ) deep vein thrombosis ( DVT ) leg treat minimally 6 maximally 12 month therapeutic dos anticoagulant , i.e . LMWH VKA new anticoagulant trial 2 . Written inform consent 3 . Indication longterm anticoagulant therapy ( e.g . metastasized disease , chemotherapy ) 1 . Legal age limitation ( country specific ) , minimum age least 18 year 2 . Indications anticoagulant therapy DVT PE 3 . Any contraindication list local labeling LMWH VKA 4 . Childbearing potential without proper contraceptive measure , pregnancy breastfeed 5 . Life expectancy &lt; 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>Heparin , Low-Molecular-Weight</keyword>
	<keyword>4-Hydroxycoumarins</keyword>
	<keyword>recurrent venous thrombosis</keyword>
</DOC>